Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd. covers the month of March 2018, with a report date of March 14, 2018. The filing serves as an update regarding the advancement of the CGEN-15001T program by the Company's partner, Bayer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate development and does not contain financial statements or quantitative financial data.
Material Changes
The primary material update concerns the collaboration with Bayer. Following a press release on February 21, 2018, the American Association for Cancer Research (AACR) published an abstract for its 2018 annual meeting. The abstract, titled "Discovery and preclinical characterization of BAY 1905254 a novel immune checkpoint inhibitor for cancer immunotherapy targeting the immunoglobulin-like domain containing receptor 2 (ILDR2)," confirms Bayer's plans to advance BAY 1905254 into first-in-human trials in 2018.
Guidance, Outlook, and Risks
Management commentary is limited to the confirmation of the clinical trial timeline for the BAY 1905254 candidate. The filing does not provide specific financial guidance, discuss general risks, or detail contingencies beyond the referenced clinical development plans.
Investor Verification Points
- Verify the publication of the AACR abstract regarding BAY 1905254 on the AACR website.
- Confirm the timeline for Bayer's initiation of first-in-human trials for BAY 1905254 in 2018.
- Review the February 21, 2018 press release referenced in this filing for prior context on the CGEN-15001T program.